Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

October 31, 2012

Conditions
Stomach NeoplasmsAdvanced Gastric Cancer
Interventions
DRUG

axitinib

Twice daily oral dose of axitinib continuously depending upon side effects observed. Starting dose is 5mg twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

DRUG

capecitabine

Given orally twice daily for 14 days followed by 7 days of drug free period. Starting dose is 1000mg/m\^2 twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

DRUG

cisplatin

Given through a vein on Day 1 of every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. The starting dose is 80 mg/m\^2 on day 1.

Trial Locations (5)

Unknown

Pfizer Investigational Site, Kashiwa

Pfizer Investigational Site, Yufu

410-769

Pfizer Investigational Site, Goyang-si

463-707

Pfizer Investigational Site, Seongnam-si

110-744

Pfizer Investigational Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY